What Limits Content Uniformity in 0.2% Butorphanol Tartrate Tablet Blends?

Direct compression of a veterinary-grade butorphanol tartrate API at a dose of 1.0–5.0 mg per core generates an API mass fraction below 2.0% w/w when the core weight is 300 mg. Under these conditions, random sampling error and low drug loading combine to produce assay RSD values outside the USP <905> acceptance value unless the API is pre-blended. The preferred method is a two-stage geometric dilution: a 1:10 pre-blend with lactose monohydrate Ph. Eur 1064, passed through a 0.850 mm screen, followed by a second 1:10 dilution with microcrystalline cellulose PH-102 and pregelatinized starch. The dilution sequence is not interchangeable; adding the API directly to the final blender load frequently leaves local API aggregates that are not detected by a single thief sample. Blending is run in a 100 L bin blender at 8–10 rpm for 15–20 min, with an intensifier bar at 1440 rpm for the final 3 min. The resulting powder RSD should be ≤ 3.0% by stability-indicating HPLC before the blend is discharged to the tablet press hopper.

If the supplier certificate of analysis reports a D90 exceeding 75 µm, the API is passed through a quadro comil with a 0.457 mm rasp screen before dilution. Failure to mill is observed directly on tablet content uniformity: the USP <905> Stage 1 acceptance value may rise above 15.0 for the first 10 units. Compression is performed on a rotary press with 10.5 mm round concave tooling. Compression force is held at 8–12 kN to target hardness of 5–7 kp and disintegration below 15 min in 0.1 N hydrochloric acid. Magnesium stearate is limited to 0.5% w/w; exceeding 1.0% w/w delays disintegration by more than 2 min and reduces tablet tensile strength. Blend hold time at RH >60% beyond 24 h causes agglomeration and weight variation on the force feeder. The granulation-free route is therefore viable only when the API is milled, excipients are dried to loss on drying ≤ 2.0%, and the compression suite is humidity-controlled. Published data for a singly approved veterinary oral tablet are limited; a development batch must generate canine bioavailability data rather than assume proportionality to the injectable dose.

Production-scale sterile injectable lines handling butorphanol tartrate at 10 mg/mL as butorphanol base require a closed processing train from API dispensing to vial sealing because the API is a Schedule IV opioid under 21 CFR 1301.72. The bulk solution is compounded in Water for Injection meeting USP <1231>, adjusted with 1 N hydrochloric acid or sodium hydroxide to a pH of 3.5–5.5, and brought to isotonicity with sodium chloride at 9.0 g/L. A nitrogen overlay is maintained when the oxygen headspace exceeds 2.0% v/v; amber Type I glass vials conforming to USP <660> reduce light-induced degradation during terminal storage. Sterile filtration through a 0.22 µm PVDF membrane is used either as the sole sterilisation step or as a bioburden-reduction step before moist heat sterilisation at 121°C for 15 min to an F0 ≥12 min. Filter integrity is confirmed by bubble point at not less than 3.2 bar, with a bacterial retention claim under ASTM F838-20. If thermal degradation products exceed ICH Q3B thresholds after 121°C, the fill-finish route is switched to aseptic filtration in an ISO 5 unidirectional airflow zone with an ISO 7 background, as required by 21 CFR 211.42. Vials are depyrogenated by dry heat at 250°C for at least 30 min; elastomeric closures are selected for low extractables under USP <381> and USP <1663>.

Particulate matter is controlled by light obscuration under USP <788>. Small-volume parenterals must contain no more than 6000 particles at ≥10 µm and 600 particles at ≥25 µm per container. A pH drift greater than 0.3 units during terminal sterilisation signals salt disproportionation or packaging interaction and requires reformulation. Multi-dose vials require an antimicrobial effectiveness test meeting USP <51>; single-dose vials omit the preservative but then cannot support repeated entry without microbial risk. On automated aseptic filling lines, batch-to-batch variance is commonly introduced by peristaltic tubing fatigue and by stopper feed interruptions; fill volume RSD should be held below 1.5% for a 2 mL presentation to ensure label compliance.

Capsule Filling and Powder Segregation Boundaries

Automated capsule filling of butorphanol tartrate low-dose blends on a dosator-equipped machine at 50,000 capsules/hour is sensitive to powder bed collapse and electrostatic charging. For a size 3 hard gelatin capsule containing 1.0–2.0 mg API in a 150 mg net fill, the final API fraction is 0.7–1.3% w/w. A pre-blend of API with microcrystalline cellulose PH-102 at 1:10 is prepared, followed by dilution with lactose monohydrate and 0.25% w/w fumed silica. The glidant is added last because its high surface area displaces API on excipient active sites and can slow dissolution if incorporated before the API is fully distributed. Powder flow is characterised by bulk density 0.40–0.50 g/mL and a Carr index below 20%. If the Carr index exceeds 25%, dosator pin fill weight variability increases beyond 3.0% RSD. Loss on drying of the final blend should be ≤ 2.0%; moisture above 4.0% causes sticking to the dosator pins and capsule shells.

Content uniformity is evaluated by USP <905> on 10 capsules with an acceptance value ≤ 15.0. If the first stage fails, the second stage requires testing of 20 additional units, which is costly for a controlled substance API. Capsule shell selection matters. Gelatin capsules at RH <40% become brittle, while HPMC capsules at RH >60% can cross-link and delay release. For formulations with fumed silica above 0.5% w/w, dissolution in 0.1 N hydrochloric acid is checked because hydrophobic silica can retard wetting. A desiccant and HDPE bottle with an induction-sealed liner are used for bulk packaging to hold moisture below the capsule specification. Batch reconciliation under 21 CFR 1304.22 is required at every transfer stage because discarded powder retains recoverable controlled substance.

When Albumin-Free Aqueous Vehicles Replace Isotonic Saline in Oral Solutions

When a butorphanol tartrate API powder is transferred from a sterile injectable workstream into an oral liquid dosage form, the isotonic saline vehicle is replaced by a buffered aqueous vehicle that retains the tartrate salt in solution but does not create a precipitation risk through free base loss. The pH is maintained between 4.0 and 5.0 using a citrate buffer; above 5.5, precipitation of the lipophilic free base can occur at high concentration. The vehicle is prepared with 0.1% w/w sodium benzoate and 0.1% w/w potassium sorbate as a preservative system when room-temperature storage is required. A non-preserved formulation is possible only if the beyond-use date is shortened to the limit specified in USP <795>. Compounding from bulk API requires a controlled non-sterile environment; the work surface is cleaned with a high-alcohol swab before and after handling because butorphanol tartrate is a Schedule IV controlled substance and must be reconciled under 21 CFR 1304.22.

Geometric dilution in a glass mortar is used for batch sizes below 100 mL; larger batches use a propeller mixer at 500–1000 rpm for 20 min. The final solution is filtered through a 100 µm screen to remove agglomerates. Palatability agents are added only after the pH measurement is recorded; some flavor systems containing citric acid can lower the pH below 3.5 and alter preservative ionisation. At pH values near 3.0, sodium benzoate shifts toward benzoic acid and can reduce antimicrobial activity. The oral solution is packaged in amber glass or polyethylene terephthalate with a child-resistant closure because butorphanol tartrate retains opioid activity by ingestion.

Wet granulation of butorphanol tartrate API in an aqueous binder system introduces a migration risk because the tartrate salt dissolves in the granulating fluid and is carried to the granule surface during drying. This surface enrichment is typically invisible to a single blend sample but appears as an elevated USP <905> acceptance value after tableting. For a 65 L high-shear mixer, the granulation sequence uses an impeller speed of 300 rpm and a chopper speed of 1500 rpm. Water addition is held at 12–15% w/w with 3.0% w/w PVP K30 binder dissolved in the granulating fluid. Wet massing lasts 4 min, after which the granules are transferred to a fluid-bed dryer at 45°C inlet air until loss on drying is 1.5–2.5%. An alternative approach replaces the aqueous granulating fluid with 95% ethanol or isopropanol, which lowers API solubility in the binder and reduces migration. However, organic granulation requires explosion-proof equipment and an ICH Q3C residual solvent monograph.

The dried granules are milled through a 1.0 mm screen. Granules with a Carr index above 25% require 0.2% w/w colloidal silicon dioxide before compression. Fumed silica above 1.0% w/w can retard dissolution and is not used. A high-shear wet granulation route is preferable to direct compression only when the final tablet dose falls below 0.5 mg, because the additional excipient surface area reduces the relative influence of API particle size on blend uniformity. In that dose range, granule porosity must still be controlled; over-drying below 1.0% moisture produces brittle granules that segregate on the press force feeder.

Premix Carrier Homogeneity Is Not a Regulatory Default for Schedule IV Opioid APIs

Butorphanol tartrate is not approved in the United States as a medicated feed premix for food-producing species, and 21 CFR 530.11(b) prohibits extralabel use in animal feed. A manufacturer attempting a premix-bound delivery for a non-food animal would still need to address the same homogeneity and stability issues as any low-dose carrier blend. If a lactose monohydrate or soybean meal carrier is selected, the API is incorporated by stepwise dilution to 0.10–0.50% w/w. Ten thief samples are taken after blending for 20 min in a twin-ribbon mixer; the RSD should remain ≤ 5.0%. Published data for this specific configuration are limited.

Moisture in the carrier above 8.0% promotes caking and microbial growth; desiccants are required for bulk fiber drums. Dust containment is handled in an isolator with HEPA H14 filtration and a downflow booth because butorphanol tartrate is a controlled substance. In all cases, the premix route is considered only after a parenteral or oral solid dosage form has been rejected for the target species and the regulatory status has been verified with the competent authority.